Literature DB >> 29031763

Correlation between the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test in patients with narcolepsy participating in two clinical trials of sodium oxybate.

Milton Erman1, Helene Emsellem2, Jed Black3, Fannie Mori4, Geert Mayer5.   

Abstract

BACKGROUND: In evaluating pathologic sleepiness, the Epworth Sleepiness Scale (ESS) assesses subjective sleep propensity; the Maintenance of Wakefulness Test (MWT) is an objective measure of the ability to stay awake. This analysis evaluated the strength of the correlation between ESS and MWT with regard to absolute values in scores.
METHODS: Data were analyzed separately from the intent-to-treat populations of two eight-week clinical trials of sodium oxybate for the treatment of narcolepsy, SXB-15 and SXB-22. For all treatment groups, correlations between ESS and MWT were evaluated at baseline, week four, and week eight using the Pearson product-moment correlation coefficient.
RESULTS: Overall, correlations across all treatment groups in each study described an inverse relationship, reflecting the scoring of each measure (ie, whereas higher ESS scores indicate greater sleepiness, higher MWT scores indicate a greater ability to remain awake). Significant correlations of low-to-moderate strength were observed at all time points in both studies. In SXB-15, correlation coefficients were -0.272, -0.365, and -0.343 at baseline (n = 221), week four (n = 212), and week eight (n = 205), respectively, with all P < 0.0001. Similarly, in SXB-22, correlation coefficients were -0.302 (n = 216), -0.418 (n = 211), and -0.432 (n = 196) at the three time points, respectively, also with all P < 0.0001.
CONCLUSION: Although all correlations showed statistical significance, they were of low-to-moderate strength. These results indicate that ESS and MWT measure features of pathologic sleepiness that may be distinct, but partially overlapping. These data corroborate those of other studies, suggesting that physiologic mechanisms that regulate alertness and sleep propensity may function somewhat independently.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ESS; MWT; Sodium oxybate

Mesh:

Substances:

Year:  2017        PMID: 29031763     DOI: 10.1016/j.sleep.2017.07.015

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  7 in total

1.  Assessing readiness to drive in adolescents with narcolepsy: what are providers doing?

Authors:  David G Ingram; Ann Marie Marciarille; Zarmina Ehsan; Gayln V Perry; Teresa Schneider; Baha Al-Shawwa
Journal:  Sleep Breath       Date:  2019-02-08       Impact factor: 2.816

2.  Sleep-Related Breathing Disorders in Multiple Sclerosis: Prevalence, Features and Associated Factors.

Authors:  Chiara Zecca; Mauro Manconi; Davide Sparasci; Francesco Fanfulla; Raffaele Ferri; Debora Aricò; Daniela Distefano; Emanuele Pravatà; Raphael Heinzer; José Haba-Rubio; Mathieu Berger; Gianna Carla Riccitelli; Claudio Gobbi
Journal:  Nat Sci Sleep       Date:  2022-04-20

3.  A randomized study of solriamfetol for excessive sleepiness in narcolepsy.

Authors:  Michael J Thorpy; Colin Shapiro; Geert Mayer; Bruce C Corser; Helene Emsellem; Giuseppe Plazzi; Dan Chen; Lawrence P Carter; Hao Wang; Yuan Lu; Jed Black; Yves Dauvilliers
Journal:  Ann Neurol       Date:  2019-03       Impact factor: 10.422

4.  Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.

Authors:  Chiara Zecca; Mauro Manconi; Davide Sparasci; Claudio Gobbi; Anna Castelnovo; Gianna Carla Riccitelli; Giulio Disanto
Journal:  J Neurol       Date:  2022-05-04       Impact factor: 6.682

5.  Evaluation of psychometric properties of patient-reported outcome measures frequently used in narcolepsy randomized controlled trials: a systematic review.

Authors:  Aaron Schokman; Yu Sun Bin; Diana Naehrig; Janet M Y Cheung; Kristina Kairaitis; Nick Glozier
Journal:  Sleep       Date:  2022-10-10       Impact factor: 6.313

6.  Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management.

Authors:  Chitra Lal; Terri E Weaver; Charles J Bae; Kingman P Strohl
Journal:  Ann Am Thorac Soc       Date:  2021-05

7.  Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.

Authors:  Aleksandar Videnovic; Amy W Amara; Cynthia Comella; Paula K Schweitzer; Helene Emsellem; Kris Liu; Amanda L Sterkel; Mildred D Gottwald; Joshua R Steinerman; Philip Jochelson; Katie Zomorodi; Robert A Hauser
Journal:  Mov Disord       Date:  2021-06-30       Impact factor: 10.338

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.